CAJ | 학술논문

背景：传统的氨基水杨酸制剂、激素和免疫抑制剂不能满足部分难治性溃疡性结肠炎（ UC）患者的治疗需求，生物制剂的出现给这部分患者带来了希望。目的：评估英夫利西单抗对难治性UC的临床疗效。方法：采用回顾性研究方法，收集2012年12月至2014年1月在哈尔滨医科大学附属第二医院住院治疗，因激素无效或激素依赖而使用英夫利西单抗治疗的中、重度活动期UC患者12例。疗程中以改良Mayo评分系统评估UC活动性，以评价英夫利西单抗的临床疗效。结果：12例患者均完成英夫利西单抗治疗并随访38周，临床表现均有不同程度的改善，6周、22周和38周有效率分别为66.7%、83.3%和91.7%，组间差异均有统计学意义（ P﹤0.05）。结论：英夫利西单抗对难治性UC疗效较好，具有临床应用价值。
배경：전통적안기수양산제제、격소화면역억제제불능만족부분난치성궤양성결장염（ UC）환자적치료수구，생물제제적출현급저부분환자대래료희망。목적：평고영부리서단항대난치성UC적림상료효。방법：채용회고성연구방법，수집2012년12월지2014년1월재합이빈의과대학부속제이의원주원치료，인격소무효혹격소의뢰이사용영부리서단항치료적중、중도활동기UC환자12례。료정중이개량Mayo평분계통평고UC활동성，이평개영부리서단항적림상료효。결과：12례환자균완성영부리서단항치료병수방38주，림상표현균유불동정도적개선，6주、22주화38주유효솔분별위66.7%、83.3%화91.7%，조간차이균유통계학의의（ P﹤0.05）。결론：영부리서단항대난치성UC료효교호，구유림상응용개치。
Background:Patients with refractory ulcerative colitis( UC ) cannot benefit from the conventional aminosalicylic acids,steroids and immunosuppressants. The emergence of biological agents offers new opportunities for these patients. Aims:To evaluate the clinical efficacy of infliximab for treating patients with refractory UC. Methods:Twelve patients with moderate to severe active UC admitted from Dec. 2012 to Jan. 2014 at the Second Affiliated Hospital of Harbin Medical University were retrospectively enrolled. All of them were steroids-refractory or steroids-dependent and infliximab therapy was then administered. Modified Mayo score was used to evaluate the disease activity and the efficacy of infliximab. Results:All patients completed the infliximab therapy and a 38-week follow-up. After treatment,the clinical manifestations were improved with varying degrees,and the efficacy at the 6th,22nd and 38th weeks was 66. 7%,83. 3% and 91. 7%, respectively,with significant differences between any two time points(P﹤0. 05). Conclusions:Infliximab is effective and practical for the treatment of refractory UC.